International Agency for Research on Cancer (IARC) - Summaries & Evaluations
VOL.: 26 (1981) (p. 237)
CAS No.: 3778-73-2
Chem. Abstr. Name: 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)-tetrahydro-, 2-oxide
5. Summary of Data Reported and Evaluation
5.1 Experimental data
Isophosphamide was tested in four studies in mice and in one in rats
by subcutaneous or intraperitoneal administration. In one study in
mice with intraperitoneal injection it produced an increased incidence
of lung adenomas. The other four studies, although indicating a
carcinogenic effect, could not be evaluated.
Isophosphamide can induce teratogenic effects in mice and
embryolethality at doses nontoxic to the mother. Isophosphamide is
mutagenic in bacteria and produced chromosomal aberrations in Chinese
hamster bone-marrow cells.
5.2 Human data
Isophosphamide has been used to a limited but increasing extent since
the early 1970s as an antineoplastic and immunosuppressive drug.
No data were available to evaluate the teratogenic or mutagenic
potential or chromosomal effects of isophosphamide in humans.
No case report or epidemiological study on isophosphamide was
available to the Working Group.
There is limited evidence for the carcinogenicity of isophosphamide
in mice and rats.
In the absence of data on humans, no evaluation can be made of the
carcinogenic risk of isophosphamide to man.
For definition of the italicized terms, see Preamble Evaluation.
Subsequent evaluation: Suppl. 7 (1987) (p. 65: Group 3)
Synonyms for Isophosphamide
- A 4942
- Asta Z 4942
- 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosp horine 2-oxide
- Holoxan 1000
- NSC 109724
- Z 4942
Last updated: 8 April 1998